Press

Lobe Sciences to Present at MONEYSHOW VIRTUAL EXPO November 10, 2022

Nov 9 • 1 min read

Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF) today announced that Philip Young, CEO and Executive Director, will present at the MONEYSHOW VIRTUAL EXPO, November 10th at 10:40AM EDT. The presentation will be available on demand through the MONEYSHOW VIRTUAL EXPO Meeting site at this link, Lobe Sciences is Developing Psychedelic Derived Medicines for Neurologic and Brain…

Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin

Nov 9 • 2 min read

-Beckley Psytech, a clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, today announced that the first participant has been dosed in its Phase I clinical trial (NCT05434156) of ELE-101, a novel, short-acting psychedelic compound which is intended to serve as a possible treatment for depression. The trial is…

PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA

Nov 9 • 2 min read

PharmAla Biotech (CSE:MDMA) is pleased to announce that it has submitted its pre-IND data meeting package to the US Food and Drug Administration in advance of its pre-IND meeting scheduled for later this month. PharmAla will be requesting FDA feedback on the nonclinical and CMC development plan to support the initial clinical trial for ALA-002….

Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video

Nov 9 • 1 min read

Algernon Pharmaceuticals (CSE: AGN | OTCQB: AGNPF) – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently granted permission to conduct a Phase 1 clinical study of DMT for the treatment of stroke. Watch the Video here. About CEO Clips: CEO Clips –…

Universal Ibogaine Announces Formation of Advisory Board

Nov 8 • 4 min read

Universal Ibogaine Inc. (TSXV:IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to announce the formation of an external Advisory Board as part of its strategic plans and mission to deliver medicalized ibogaine-centered addiction care and to undertake a planned clinical trial application process. The UI Advisory Board is intended to allow…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435